Study of compliance with prescription information sheet of trastuzumab prescriptions in a tertiary level hospital

Vargas-Rivas, JE; Montes-Casas, MM; Cancela-Diez, B; Martínez-Martínez, F; Sabater-Hernández, D; Calleja-Hernández, MA

Study of compliance with prescription information sheet of trastuzumab prescriptions in a tertiary level hospital

Vargas-Rivas, JE Montes-Casas, MM Cancela-Diez, B Martínez-Martínez, F Sabater-Hernández, D

Calleja-Hernández, MA

Permalink

Publication Type:: Journal Article
Citation:: Farmacia Hospitalaria, 2012, 36 (3), pp. 135 - 140
Issue Date:: 2012-05-01

Closed Access

	Filename	Description	Size
	2013003433OK.pdf		158.89 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Vargas-Rivas, JE	en_US
dc.contributor.author	Montes-Casas, MM	en_US
dc.contributor.author	Cancela-Diez, B	en_US
dc.contributor.author	Martínez-Martínez, F	en_US
dc.contributor.author	Sabater-Hernández, D https://orcid.org/0000-0001-7419-8740	en_US
dc.contributor.author	Calleja-Hernández, MA	en_US
dc.date.available	2011-02-09	en_US
dc.date.issued	2012-05-01	en_US
dc.identifier.citation	Farmacia Hospitalaria, 2012, 36 (3), pp. 135 - 140	en_US
dc.identifier.issn	1130-6343	en_US
dc.identifier.uri	http://hdl.handle.net/10453/29769
dc.description.abstract	Introduction: This study compares trastuzumab's actual conditions of use in clinical practice with those officially described on its summary of product characteristics. We also measure the cost associated with its use. Methods: Observational study of the prescription/indication of trastuzumab in a tertiary hospital from January 2006 to 31 December 2007. We analysed whether trastuzumab use in clinical practice complied with its summary of product characteristics, concerning the following: HER2 over expression, indication (breast cancer), treatment plan, line of treatment, dosage, frequency and number of cycles. To measure cost, we calculated the total number of milligrams used and then multiplied it by the laboratory's sale price per milligram plus VAT. Results: All patients (n = 77) used trastuzumab for breast cancer. Sixty-two point two percent of patients presented with HER2+++ over expression. Twenty-nine treatment plans were used, that were not authorised on the summary of product characteristics. The total trastuzumab cost during the study period was 1537 622.73. Conclusions: Although trastuzumab is always used for breast cancer, it is used in conditions other than those described on its summary of product characteristics, both for HER2 over expression and treatment plans. © 2010 SEFH. Published by Elsevier España, S.L. All rights reserved.	en_US
dc.relation.ispartof	Farmacia Hospitalaria	en_US
dc.relation.isbasedon	10.1016/j.farma.2011.02.009	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Carcinoma	en_US
dc.subject.mesh	Breast Neoplasms	en_US
dc.subject.mesh	Cisplatin	en_US
dc.subject.mesh	Taxoids	en_US
dc.subject.mesh	Paclitaxel	en_US
dc.subject.mesh	Carboplatin	en_US
dc.subject.mesh	Vinblastine	en_US
dc.subject.mesh	Receptor, erbB-2	en_US
dc.subject.mesh	Antibodies, Monoclonal, Humanized	en_US
dc.subject.mesh	Antineoplastic Agents, Hormonal	en_US
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols	en_US
dc.subject.mesh	Deoxycytidine	en_US
dc.subject.mesh	Docetaxel	en_US
dc.subject.mesh	Drug Administration Schedule	en_US
dc.subject.mesh	Drug Costs	en_US
dc.subject.mesh	Drug Labeling	en_US
dc.subject.mesh	Drug Prescriptions	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Guideline Adherence	en_US
dc.subject.mesh	Hospitals, University	en_US
dc.subject.mesh	Neoplasm Proteins	en_US
dc.subject.mesh	Practice Guidelines as Topic	en_US
dc.subject.mesh	Prescription Fees	en_US
dc.subject.mesh	Prospective Studies	en_US
dc.subject.mesh	Receptor, ErbB-2	en_US
dc.subject.mesh	Spain	en_US
dc.subject.mesh	Trastuzumab	en_US
dc.subject.mesh	Vinorelbine	en_US
dc.title	Study of compliance with prescription information sheet of trastuzumab prescriptions in a tertiary level hospital	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	36	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	36	en_US

Abstract:

Introduction: This study compares trastuzumab's actual conditions of use in clinical practice with those officially described on its summary of product characteristics. We also measure the cost associated with its use. Methods: Observational study of the prescription/indication of trastuzumab in a tertiary hospital from January 2006 to 31 December 2007. We analysed whether trastuzumab use in clinical practice complied with its summary of product characteristics, concerning the following: HER2 over expression, indication (breast cancer), treatment plan, line of treatment, dosage, frequency and number of cycles. To measure cost, we calculated the total number of milligrams used and then multiplied it by the laboratory's sale price per milligram plus VAT. Results: All patients (n = 77) used trastuzumab for breast cancer. Sixty-two point two percent of patients presented with HER2+++ over expression. Twenty-nine treatment plans were used, that were not authorised on the summary of product characteristics. The total trastuzumab cost during the study period was 1537 622.73. Conclusions: Although trastuzumab is always used for breast cancer, it is used in conditions other than those described on its summary of product characteristics, both for HER2 over expression and treatment plans. © 2010 SEFH. Published by Elsevier España, S.L. All rights reserved.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/29769